Aspirin use has been shown to be effective in both primary prevention of CRC (at daily doses ≥ 300 mg for about 5 years) and secondary prevention (at daily doses of 81-325 mg daily) of colorectal adenomas. The decrease in colon cancer risk with aspirin use may vary among population subgroups. However, body mass index, physical activity, and plasma C-peptide levels were shown to not have a significant impact on aspirin's effect on CRC risk.
The USPSTF recommends the use of low-dose aspirin for the primary prevention of CRC in adults aged 50-59 years who are not at increased bleeding risk, have a life expectancy of at least 10 years, and are willing to take the aspirin daily for at least 10 years. The choice to initiate low-dose aspirin use to prevent CRC in patients aged 60-69 years should be an individual one, according to the USPSTF. The organization found that evidence is insufficient to support aspirin use for primary prevention of CRC in adults younger than 50 years or adults aged 70 years or older.
Medscape © 2020 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: Mary L. Windle. Fast Five Quiz: Aspirin Use - Medscape - Jan 03, 2020.